In part 8 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about plans to study Empagliflozin effects in patients with prediabetes.
Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.
Transcript of this video segment:
Steve: Are there any future studies being done for prediabetes?
Dr. Seck: for Empagliflozin?
Dr. Seck: We are looking at data we have available, think about other ways to provide value for patient population that we have currently not covered in our labeling. You might be aware that we have already started studies on heart failure patients. These are studies in patients who have established heart failure and its independent of whether or not they have type 2 diabetes. Or even patients without diabetes, because we believe that mechanism of action will also work in patients without type 2 diabetes. So these studies just started to involve. Its called empiric studies. Its two different studies with 7,000 patients planned to be enrolled. We are very much looking forward to the results of these studies.
Steve: When would the results come out? I know it depends…
Dr. Seck: It’s always estimated when you start the study but the expectation is around 2020 we should see the results for this program.